IMUNON Presents Ovarian Cancer Treatment Update and Phase 3 Trial Progress

IMUNON, Inc. is presenting an update on its IMNN-001 development program for treating newly diagnosed advanced ovarian cancer. The event will feature presentations from key opinion leaders, clinicians, statistical experts, and IMUNON executives. Positive data from the Phase 2 OVATION 2 Study and an MRD study will be reviewed, along with updates on the ongoing Phase 3 OVATION 3 pivotal trial. Investors, stakeholders, and those interested in ovarian cancer treatment and women's health are encouraged to attend.